Cardiac arrhythmia due to ledipasvir/sofosbuvir Iranian counterpart, commercially named as Ledibiox: A case report

Document Type : Case Report

Authors

1 Cardiologist, Cardiovascular Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

2 Medical student, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Sofosbuvir is an antiviral drug that entirely revolutionized the treatment of hepatitis C. This drug has an Iranian commercial brand, which is known as Ledibiox. Several adverse events have been reported with this drug, including syncope, pancolitis, and exacerbated pulmonary arterial hypertension; however, arrhythmia rarely has been described through the literature. Here, we report a 40-year-old Caucasian man who presented with chest pain, tachycardia, blurred vision, and severe headache; whose electrocardiography showed an atrial tachycardia along with a block. It seems that Sofosbuvir toxicity can cause arrhythmia, and the drug prescription should be halted in this situation.

Keywords

References

1.           Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040-6.
2.           Merat S. Hepatitis C Virus Guideline in Iran. Govaresh. 2017;22(3):182-5.
3.           In brief: severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther. 2015;57(1466):58.
4.           Gillette P, Crawford F, Zeigler V. Mechanisms of atrial tachycardias. Card Electrophysiol. 1990:559-63.
5.           Lown  B, Marcus  F, Levine  HD. Digitalis and Atrial Tachycardia with Block. N Eng J Med. 1959;260(7):301-9.
6.           Diseases AAftSoL, America IDSo. Recommendations for testing, managing, and treating hepatitis C. 2014.
7.           Kowdley K, Hassanein T, Gane E, Hyland R, Ma J, Symonds W, et al. 842 sofosbuvir safety and tolerability in 741 patients treated for up to 24 weeks. J Hepatol. 2013;58:S345.
8.           Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J hepatol. 2015;62(2):286-93.
9.           Bagate F, Lazarus A, Fontaine H, Pecriaux C, Sogni P, Pol S, et al. 0428: Cardiac arrhythmia after initiation of sofosbuvir-including regimen in patients with chronic hepatitis C virus infection. Arch Cardiovasc Dis Suppl. 2016;8(1):76.
10.        Lashen S, Sanhoury M. Syncope Following Sofosbuvir Therapy for Chronic Hepatitis C: A Report of Two Cases. J Liver Res Disord Ther. 2016;2(4):00032.
 
Journal of Cardio-Thoracic Medicine
Volume 8, Issue 3
September 2020
Pages 679-683

Files

Share

How to cite

Statistics